2024 ASCO® Annual Meeting Post Conference Update

Thanks for stopping by our booth for a deep dive into the future of oncology diagnostics!

If you weren’t able to make it to ASCO, see what you missed below.

May 31-June 4, 2024
Chicago, IL & Online
Our team

The Sysmex Inostics Team was excited to interact with booth visitors on how our comprehensive clinical trial services can address liquid biopsy needs in oncology!

Our booth

We showcased the utility of plasma-based ctDNA diagnostic assays for optimizing oncology treatment!


We shared our latest clinical collaborations in advancing liquid biopsy use in oncology trials.


We discussed the latest insights on leveraging our HPV-SEQ liquid biopsy assay for developing novel therapies in HPV+ cancers.


You missed freshly baked cookies!


And missed the action at our booth that included discussions on LBx in cancer diagnostics and a short HPV quiz to gain bragging rights!

Affiliated Presentations

Exciting results presented using our targeted assays in metastatic breast cancer and HPV+ oropharyngeal cancer.

Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2- metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial.

Presented by: Dr. Federico Rojo

Hospital Universitario Fundación Jiménez Díaz;
GEICAM Spanish Breast Cancer Group, Barcelona, Spain

Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: “TARGET HPV”

Selected for rapid oral presentation

Presented by: Dr. Ari Rosenberg

University of Chicago, Department of Medicine, Chicago, IL

2024 ASCO Annual Meeting Materials

Download the brochure of our assays we showcased at ASCO.